Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44.2M
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
34.7M
-
Shares change
-
-1.94M
-
Total reported value, excl. options
-
$148M
-
Value change
-
-$6.55M
-
Put/Call ratio
-
1.43
-
Number of buys
-
33
-
Number of sells
-
-22
-
Price
-
$4.27
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q4 2023
65 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q4 2023.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.7M shares
of 44.2M outstanding shares and own 78.63% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (10.9M shares), BAKER BROS. ADVISORS LP (10.1M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (4.13M shares), Boxer Capital, LLC (2.57M shares), BlackRock Inc. (1.1M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.04M shares), VANGUARD GROUP INC (1.01M shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (511K shares), GEODE CAPITAL MANAGEMENT, LLC (349K shares), and Sio Capital Management, LLC (320K shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.